CLIMB BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
CLIMB BIO, INC. (CLYM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-06-30 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-09-30 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-06-30 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- CLIMB BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-06 | 0.00% 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-06 | 0.00% 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-12 | 0.00% 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-25 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-28 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-06 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-09-13 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |